These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1541530)

  • 1. Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
    Marsili I; Pizza M; Giovannoni F; Volpini G; Bartalini M; Olivieri R; Rappuoli R; Nencioni L
    Infect Immun; 1992 Mar; 60(3):1150-5. PubMed ID: 1541530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
    Cropley I; Douce G; Roberts M; Chatfield S; Pizza M; Marsili I; Rappuoli R; Dougan G
    Vaccine; 1995 Dec; 13(17):1643-8. PubMed ID: 8719514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
    Simondon F; Yam A; Gagnepain JY; Wassilak S; Danve B; Cadoz M
    Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):927-32. PubMed ID: 9031875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The development of a new generation of pertussis vaccine].
    Chuprinina RP; Bychenko BD; Smirnov VD; Maksiutov RV; Eglit IuKh
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Oct; (10):89-94. PubMed ID: 2075771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.
    Nascimento IP; Dias WO; Mazzantini RP; Miyaji EN; Gamberini M; Quintilio W; Gebara VC; Cardoso DF; Ho PL; Raw I; Winter N; Gicquel B; Rappuoli R; Leite LC
    Infect Immun; 2000 Sep; 68(9):4877-83. PubMed ID: 10948100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine].
    Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.
    Relyveld E; Oato NH; Guérin N; Coursaget P; Huet M; Gupta RK
    Vaccine; 1991 Nov; 9(11):843-50. PubMed ID: 1759508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards the development of new vaccines against whooping cough.
    Rappuoli R; Podda A; Pizza M; Covacci A; Bartoloni A; de Magistris MT; Nencioni L
    Vaccine; 1992; 10(14):1027-32. PubMed ID: 1471424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; De Luca EC; Contu B; Furlan R; Maida A; Moiraghi A; Stramare D; Titone L; Uxa F; Di Pisa F; Peppoloni S
    J Pediatr; 1994 Jun; 124(6):921-6. PubMed ID: 8201477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
    Boucher P; Sato H; Sato Y; Locht C
    Infect Immun; 1994 Feb; 62(2):449-56. PubMed ID: 7507893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
    Vuolo AM; Lustigman B
    Biologicals; 1993 Mar; 21(1):45-52. PubMed ID: 8217117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative biological activities of acellular pertussis vaccines produced by Kitasato.
    Watanabe M; Izumiya K; Sato T; Yoshino K; Nakagawa N; Ohoishi M; Hoshino M
    Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.
    Arciniega JL; Shahin RD; Burnette WN; Bartley TD; Whiteley DW; Mar VL; Burns DL
    Infect Immun; 1991 Oct; 59(10):3407-10. PubMed ID: 1894354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.
    Roberts M; Bacon A; Rappuoli R; Pizza M; Cropley I; Douce G; Dougan G; Marinaro M; McGhee J; Chatfield S
    Infect Immun; 1995 Jun; 63(6):2100-8. PubMed ID: 7768587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.